Meropenem Panpharma (Meropenem Trihydrate)

Meropenem, the active ingredient in Meropenem Panpharma, is a carbapenem presented as an injectable solution for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary, and respiratory infections, in hospitalized adult patients. GNH USA supplies Meropenem Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by Gram‑negative and Gram‑positive bacteria.

Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication. Complicated urinary tract infections: clears infection and prevents recurrence. Hospital‑acquired pneumonia: resolves pulmonary infection and improves oxygenation. Ventilator‑associated pneumonia: eliminates pathogenic bacteria and supports respiratory recovery. Severe sepsis and septic shock: controls systemic infection and stabilises organ function.

Common adverse reactions observed with meropenem therapy include gastrointestinal and mild systemic effects.

Common Side Effects: - Nausea - Diarrhea - Rash or mild skin eruption - Headache - Elevated liver enzymes - Injection‑site phlebitis

Serious or Rare Side Effects: - Seizures, especially in patients with CNS disorders - Clostridioides difficile‑associated colitis - Anaphylaxis or severe hypersensitivity reactions - Neutropenia or agranulocytosis - Renal toxicity or acute kidney injury - Hepatic failure or severe transaminase elevation

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for adverse events.

Renal function monitoring: adjust dose in renal impairment. Hypersensitivity screening: avoid in patients with known carbapenem allergy. Seizure risk assessment: use cautiously in patients with CNS disease. Antimicrobial stewardship: reserve for infections where other agents are unsuitable. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring careful review of the patient’s regimen.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, enhancing toxicity. - Other carbapenems: concurrent use can increase risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances and renal effects. - Aminoglycosides: combined nephrotoxic potential warrants renal function monitoring. - NSAIDs: concurrent use may further impair renal function, especially in dehydrated patients.